Antares Pharma to Present at the JMP Securities Life Sciences Conference
June 16 2015 - 7:00AM
Business Wire
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn
P. Hobbs, President and Chief Executive Officer, will present at
the JMP Securities Life Sciences Conference on Tuesday, June 23,
2015 at 1:30 p.m. Eastern Time.
A live webcast of the presentation will be available via the
webcast tab under the Investor Information page of the Antares
website, www.antarespharma.com. A replay of the webcast will also
be archived on Antares’ website for 90 days following the
presentation.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral
pharmaceutical products. The Company’s product, OTREXUP™
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. Antares
Pharma is also developing QuickShot® Testosterone for testosterone
replacement therapy, and VIBEX® Sumatriptan for the acute treatment
of migraines. The Company's technology platforms include VIBEX®
disposable auto injectors, disposable multi-use pen injectors and
reusable needle-free injectors. Antares Pharma has a multi-product
deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX®
epinephrine, exenatide multi-dose pen, and another undisclosed
multi-dose pen. Our reusable needle-free injector for use with
human growth hormone (hGH) is sold worldwide by Ferring B.V.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150616005260/en/
Antares Pharma, Inc.Jack Howarth, 609-359-3016Vice President,
Corporate Affairsjhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024